# Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass

> **NCT05610475** · NA · COMPLETED · sponsor: **Yangzhou University** · enrollment: 100 (actual)

## Conditions studied

- Lung Injury, Acute

## Interventions

- **DIAGNOSTIC_TEST:** blood cell analysis, blood gas surveillance, chest radiograph and echocardiography

## Key facts

- **NCT ID:** NCT05610475
- **Lead sponsor:** Yangzhou University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610475, "Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05610475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*